- Galapagos NV (NASDAQ:GLPG) perks up 1% premarket, albeit on only 896 shares, on the heels of its announcement that it has launched a Phase 1 study of cystic fibrosis (CF) candidate GLPG3067 triggering a $7.5M milestone payment from collaboration partner AbbVie (ABBV).
- The single center study will assess GLPG3067's safety, tolerability and pharmacokinetics in 48 healthy volunteers in Belgium. The last part of the study will assess the combination of GLPG3067 and GLPG2222. Top-line data will be submitted for presentation at a future medical conference.
- The companies are working on combination therapy for CF that addresses three complementary components. They are currently testing potentiator GLPG2451 and corrector GLPG2222 in healthy volunteers and plan to add corrector GLPG2737 to make a triple combination. GLPG3067 is also a potentiator.